reports
- Jacob Mekhael
Galapagos Updated NHL phase 1/2 GLPG5101 data at EHA shows decentralis...
Galapagos will present new data from the ongoing Phase 1/2 (ATALANTA-1) study of GLPG5101 (CD19 CAR-T) at the European Hematology Association (EHA) Congress, being held 12-15 June. The results demonstrate POC for a 7 day vein-vein de-centralised CAR-T manufacturing process. Combined with the previously reported safety differentiation, we believe this could support strategic discussions as the company is exploring such options for its cell therapy business. We reiterate our Buy rating and € 37 TP...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Lewi
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighti...
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities Of the 64 patients enrolled, 61 received treatment, resulting in a 5% attrition rate, significantly lower than industry benchmarks. 95% of patients were infused with fresh, stem-like early memory CD19 CAR-T cell...
Galapagos zal nieuwe ATALANTA-1 CAR-T data presenteren op EHA 2025, me...
Galapagos zal nieuwe ATALANTA-1 CAR-T data presenteren op EHA 2025, met lage toxiciteit en snelle, gedecentraliseerde toediening van vers, early-memory-verrijkt GLPG5101 bij R/R NHL Gegevens uit de lopende ATALANTA-1 fase 1/2-studie bij een zwaar voorbehandelde patiëntengroep met recidief/refractair non-Hodgkinlymfoom (R/R NHL) tonen lage percentages van hooggradige toxiciteiten aan Van de 64 ingeschreven patiënten werden er 61 behandeld, wat resulteerde in een uitvalpercentage van 5%, aanzienlijk lager dan de benchmarks. 95% van de patiënten werd geïnfuseerd met verse,...
- Jacob Mekhael
Autolus Longer follow up at EHA maintains Aucatzyl's benefit in r/r ad...
Autolus announced updated long term data (approx. 3 years of follow up) from the phase 2 (FELIX) study of Aucatzyl (CD19 CAR-T) in r/r adult ALL to be presented at the European Hematology Association (EHA) conference, being held 12-15 June. The updated results demonstrate that Aucatzyl has maintained its benefit without the need for additional therapy with an additional 11 months of follow up as 38.4% of responders are in ongoing remission (vs. 40% at 21.5 months median follow up). We believe th...
- ING Helpdesk
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Vranken
- Wim Lewi
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study...
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients still in remission at 24 months38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel LONDON, June 12, 2025 (GLOBE NEWSWIRE...
Nextensa NV/SA : Information on the total number of voting rights a...
Nextensa NV/SA : Information on the total number of voting rights and shares PRESS RELEASE REGULATED INFORMATION Brussels, 11 June 2025, 5:40pm Nextensa NV/SA : Information on the total number of voting rights and shares In application of article 15 of the...
Nextensa SA : Informations relatives au nombre total de droits de vote...
Nextensa SA : Informations relatives au nombre total de droits de vote et d’actions COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES Bruxelles, 11 juin 2025, 17h40 Nextensa SA : Informations relatives au nombre total de droits de vote et d’actions En application de l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nextensa (la ‘Société’) communique les informations suivantes suite à l'octroi ...
Nextensa NV : Informatie betreffende het totale aantal stemrechten e...
Nextensa NV : Informatie betreffende het totale aantal stemrechten en aandelen PERSBERICHT GEREGLEMENTEERDE INFORMATIE Brussel, 11 Juni 2025, 17u40 Nextensa NV : Informatie betreffende het totale aantal stemrechten en aandelen In toepassing van artikel 15 van de wet van 2 mei 2007 op d...
KPN reports on progress of € 250m share buyback
KPN reports on progress of € 250m share buyback KPN has repurchased 2,801,895 KPN ordinary shares in the period from 2 June to 6 June 2025. The shares were repurchased at an average price of € 4.17 per share for a total consideration of € 11.7m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased until 6 June 2025 is 46,271,738 for a total consideration of € 184.0m. Transaction details of the share buyback are available ...
JDE Peet’s share buyback periodic update June 10, 2025
JDE Peet’s share buyback periodic update June 10, 2025 PRESS RELEASE Amsterdam, June 10, 2025 JDE Peet’s (EURONEXT: JDEP), the world’s leading pure-play coffee and tea company, today announced that it has repurchased 22,933 shares in the period from June 2, 2025 up to and including June 6, 2025. The shares were repurchased at an average price of EUR 24.14 per share for a total consideration of EUR 0.6 million. These repurchases were made as part of the EUR 250 million share buyback programme . The total number of shares repurchased under this programme to date is 3,691,468 ordinary sha...
Heineken N.V. reports the progress of transactions under its current s...
Heineken N.V. reports the progress of transactions under its current share buyback programme Heineken N.V. reports the progress of transactions under its current share buyback programme Amsterdam, 10 June 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 2 June 2025 up to and including 6 June 2025 a total of 70,000 shares were repurchased on exchange at an average price of € 79.04. During the same period, 70,010 shares were r...
Euronext announces volumes for May 2025
Euronext announces volumes for May 2025 Euronext announces volumes for May 2025 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 10 June 2025 – Euronext, the leading European capital market infrastructure, today announced trading volumes for May 2025. Euronext informs that the template has been aligned with the new reporting framework, which was implemented as of the first quarter 2025 results publication. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Aurélie Cohen ...
Euronext N.V.: 7 directors
Five Directors at Euronext N.V. sold after exercising options/sold 9,154 shares at between 145.000EUR and 145.927EUR. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...
- Guy Sips
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Benelux Local Champions Feedback document
Below our feedback notes written at the occasion of our annual Benelux Local Champions Conference that took place on 27 May 2025 at our historic building at Grand Place Brussels. This event offered the possibility to have one-on-one meetings and/or small group meetings with the following Benelux companies and their top management & IR: ACKERMANS & VAN HAAREN | AHOLD DELHAIZE | AKZONOBEL | ARCADIS | AZELIS | CORBION | GBL | LOTUS BAKERIES | MELEXIS | PROXIMUS | SOFINA | UMICORE
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Hyloris FDA approval for Tranexamic Acid Intravenous Premix RTU
Hyloris announced that its partner Avenacy received FDA approval for its ANDA (generic NDA) of Tranexamic Acid Intravenous Premix Ready-to-Use (RTU), with launch planned for 2H25. This product, approved through the generic ANDA pathway, is non-core for the company, as Hyloris' main focus is on the more valuable reformulation and repurposing 505(b)(2) pathway. Sales of intravenous tranexamic acid reached $ 29.1m in the 12 months up to March 2025, and we estimate Hyloris could receive approx. $ 2m...
KPN reports on progress of € 250m share buyback
KPN reports on progress of € 250m share buyback KPN has repurchased 3,355,000 KPN ordinary shares in the period from 26 May to 30 May 2025. The shares were repurchased at an average price of € 4.16 per share for a total consideration of € 13.9m. These repurchases are part of the € 250m share buyback started on 25 February 2025 and reflect KPN's commitment to structurally return additional capital to its shareholders. The total number of ordinary shares repurchased until 30 May 2025 is 43,469,843 for a total consideration of € 172.3m. Transaction details of the share buyback are available ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.